An individualised approach to antithrombotic management should be adopted in patients with atrial fibrillation and concomitant coronary artery disease with consideration to both bleeding and thrombotic risk.
- One in five patients receiving long-term anticoagulation have coronary artery disease.
- These patients present a unique challenge in balancing the risks and benefits of combined anticoagulant and antiplatelet therapies.
- The efficacy and safety of combination antiplatelet and anticoagulant therapies have been assessed recently in several trials.
- An individualised approach to antithrombotic management should be adopted in patients with dual indications, typically those with pre-existing nonvalvular atrial fibrillation presenting with an acute coronary syndrome, with consideration to both bleeding and thrombotic risks.